Tarsus Reports Q3 2026 Results, XDEMVY Sales Rise 64%
Tarsus reported $194.6 million in XDEMVY net product sales for the third quarter, up approximately 64% year over year. The company said cumulative net product sales since launch exceeded $1 billion and appointed Neera Clase as chief commercial officer.
Story updates
09:13:26 PM UTC
SquawkNews
Tarsus Pharmaceuticals reported third-quarter 2026 revenue of $194.57 million, up 63.9% from the prior-year quarter, while net loss widened to $668.33 million, or $14.4 per diluted share. Growth was driven by higher XDEMVY sales volume and improved gross-to-net discounts.Financial Highlights¹ Repor…
09:17:06 PM UTC
SquawkNews
Tarsus reported third-quarter 2026 revenue of $194.6 million, up from $118.7 million a year earlier, as XDEMVY sales grew. Net loss was $668.3 million, including $632.2 million in acquired in-process research and development expenses related to the iRenix and Alkeus acquisitions. The company ended…
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-yearSurpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launchAppointed Neera Clase as Chief Commercial OfficerManagement to…